Following the House Oversight Committee’s call to investigate the approval and price of Biogen’s new Alzheimer’s drug, Rep. Katie Porter (D-CA) is now calling on HHS’ inspector general to investigate the cozy relationship between the FDA and Biogen ahead of that approval.
Trending:
Rep. Porter calls on HHS inspector general to investigate FDA-Biogen ties prior to Aduhelm's approval